Mutations in RET (rearranged during transfection), a receptor tyrosine kinase, are found in thyroid cancer and nonsmall cell lung cancer and present a potential therapeutic target.166 Several Food and Drug Administration-approved multikinase inhibitors including vandetanib and cabozantinib have activity against RET; however, none have been approved solely on the basis of their anti-RET kinase action. Here, RET is linked to thyroid gland carcinoma.